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Arrhythmic management is needed after removal of cardiac implantable electronic devices (CIEDs).
Patients completely dependent on CIEDs need temporary device back-up until new CIEDs are implanted.
Various methods are available for device back-up, and the appropriate management varies among
patients. The duration from CIED removal to implantation of a new CIED also differs among patients.
Temporary pacing is needed for patients with bradycardia, a wearable cardioverter deﬁbrillator (WCD) or
catheter ablation is needed for patients with tachyarrhythmia, and sequential pacing is needed for
patients dependent on cardiac resynchronization therapy. The present review focuses on arrhythmic
management after CIED removal.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
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Cardiac implantable electronic devices (CIEDs) have become
increasingly important in cardiac disease management worldwide.
In fact, pacemakers, implantable cardioverter deﬁbrillators (ICDs),
and cardiac resynchronization therapy (CRT) have been used and
developed since the 1960s. With the increase in the number of
patients with CIEDs, the number of the CIED-related complications,
including infection, has also been increasing. From 1996 to 2003,
the rates of hospitalization for CIED infection reportedly increased
faster than the rates of CIED implantation [1]. In patients with CIED
infection, complete removal of all hardware, regardless of location
(subcutaneous, transvenous, or epicardial), is the recommended
treatment [2]. Various tools (traction devices, mechanical sheaths,
laser sheaths, electrosurgical sheaths, rotating threaded tip sheath,blished by Elsevier B.V. This is an
nnishii2001@yahoo.co.jpand telescoping sheaths) and methods (femoral approach, internal
jugular approach, and a hybrid method with both, transvenous and
surgical methods) have been developed for lead removal, and
favorable results have been reported [3,4]. However, data to deter-
mine the optimal duration of antimicrobial therapy for CIED infec-
tion are limited. Further, data on appropriate management after
CIED removal are also not available, although management of
arrhythmic support after CIED removal is needed until a new CIED
is implanted. In the present review, we focus on arrhythmic man-
agement from CIED removal to implantation of a new CIED.2. Before lead extraction
Before a CIED can be removed, the consequences of removal
need to be ascertained. Patients’ dependence on pacemakers, the
risk of tachyarrhythmia, and requirement of CRT must be deter-
mined, and the strategy for antiarrhythmic management should be
determined on the basis of these investigations.open access article under the CC BY-NC-ND license
Fig. 1. Temporary pacing using a permanent active ﬁxation lead. A permanent
active ﬁxation pacemaker lead was implanted. The electrode was connected to a
generator.
Fig. 2. Temporary active ﬁxation lead.
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CIED removal is associated with some problems. Therefore, whe-
ther the patient deﬁnitely needs a new CIED needs to be determined
ﬁrst. Second, until the new CIED is implanted, temporary pacing
should be set up, especially in patients completely dependent on a
pacemaker, using tools such as passive ﬁxation leads, active ﬁxation
leads, and epicardial leads.
In their prospective, controlled study, Braun et al. [5] reported
that transvenous pacing with active ﬁxation is safe and is asso-
ciated with a signiﬁcantly lower rate of pacing-related adverse
events than the standard technique of transvenous pacing using a
passive external pacing catheter. Forty-nine patients with systemic
infection and hemodynamic-relevant bradyarrhythmia were tem-
porarily paced using either a conventional pacing wire/catheter
(n¼26, reference group) or a permanent bipolar active pacing
lead, which was placed transcutaneously in the right ventricle and
connected to an external pacing generator (n¼23, external lead
group). The sensing values in the two groups were almost iden-
tical, but the median pacing threshold was signiﬁcantly higher in
the reference group (1.0 V vs. 0.6 V, Po0.05). Within comparable
durations of pacing (median: 8.2 vs. 7.7 days), there were 24
pacing-related adverse events (including dislocation, resuscitation
due to severe bradycardia, and local infection) in the reference
group but only one in the external lead group (Po0.01). None of
these complications resulted in cardiac death. The reference group
showed very high complication rates, mainly lead dislocation.
Active ﬁxation of temporary leads was only introduced in Japan in
2013. Moreover, a 2-week gap is generally observed between CIED
removal and new CIED implantation in patients with pocket
infection and a 4–6-week gap in patients with systemic infection.
Patients with passively ﬁxed temporary leads have a high risk of
complications. Therefore, especially in patients completely
dependent on pacing, permanent active ﬁxation of leads permit-
ting bipolar stimulation has been used for temporary pacing
(Fig. 1). Recently, temporary active ﬁxation of leads became
available in Japan (Fig. 2) (TUA, OSYPKA AG, Germany).
Epicardial leads are feasible for cases in which open chest
surgery is required. These leads carry a very low risk of percuta-
neous infection and lead dysfunction for a couple of weeks.
No clinical trial data are available for determining the optimal
duration of antimicrobial therapy for CIED infection. However,
therapy for 10–14 days after device removal is considered rea-
sonable when CIED infection is limited to the pocket site, while at
least 2–4 weeks of parenteral therapy after extraction of the
infected device is recommended for patients with bloodstream
infection [6].
Only one study has reported simultaneous contralateral (side-
to-side) replacement of an infected CIED [7]. A one-stage exchange
was performed in 68 consecutive patients over a 14-year period by
a single cardiologist, and dual-chamber devices were used in two-
thirds of these patients. Clinical presentations included device
erosion (41%), cellulitis or abscess (35%), and endocarditis (24%).
Fifty-nine patients (87%) were followed up for more than 1 year,
and 9 patients were lost to follow-up at 1–10 months after the
one-stage contralateral device exchange, with no newly identiﬁed
CIED infections. Additional experience with one-stage con-
tralateral device exchange is needed before it can be recom-
mended for routine use.
The duration between CIED removal and re-implantation may
vary among cases. We encountered two cases of early re-
implantation. In the ﬁrst case, the patient had CIED infection on
both sides, and open chest surgery was needed to remove all
CIEDs. An epicardial system was simultaneously implanted when
the CIEDs were removed (Fig. 3). No re-infection was noted in the
2–year follow-up period. In the other case, early re-implantationwas performed because the patient experienced dementia and
restlessness 3 days after CIED removal. In this case as well, no re-
infection was noted in the 2-year follow-up period.4. Patients with high risk of tachyarrhythmia
Patients with high-energy CIEDs are more likely to develop an
infection than patients with a pacemaker [6]. Patients with a high
risk of tachyarrhythmia should be temporarily managed using
tools such as wearable cardioverter deﬁbrillators (WCDs) and
catheter ablation.
Healy et al. [8] reported on the cost effectiveness of using WCDs
(Fig. 4) during the waiting period after infected CIED removal. The
Fig. 3. Epicardial lead implantation. (A) Before removal of the CIED. (B) A new pacemaker with an epicardial lead was simultaneously implanted during open chest surgery
for removal of the infected pacemaker.
Fig. 4. Wearable cardioverter deﬁbrillator.
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or $26,436 per quality-adjusted life-year (QALY) as compared to
discharge to home without a WCD. Discharge to a skilled nursing
facility and in-hospital monitoring resulted in higher costs and
poorer clinical outcomes. The incremental cost-effectiveness ratio
was as low as $15,392/QALY if the WCDs successfully terminated
95% of sudden cardiac arrest (SCA) events and exceeded the
$50,000/QALY willingness-to-pay threshold if their efﬁcacy was
o69%. Use of WCDs remained cost effective, assuming a 2-month
SCA risk of 5.6%, as long as the time to reimplantation was at least
2 weeks.
Tanawuttiwat et al. [9] conducted a retrospective study on all
WCD patients who underwent ICD removal because of cardiac
device infections at two referral centers. Ninety-seven patients
were included in their study. The median duration of antibiotic
use was 14.7 days. The median daily WCD use was 20 h/day andthe median duration of use was 21 days. A total of three patients
received WCD shocks. Two patients had four episodes of sus-
tained ventricular tachycardia (VT), which were successfully
terminated by the WCD. A third patient received two inap-
propriate treatments because of oversensitivity of the signal
artifact. Three patients experienced sudden death outside the
hospital while not wearing the device. Five patients died while
hospitalized. This previous study concluded that the WCD can
prevent sudden cardiac death until ICD reimplantation is possible
in patients from whom the CIED has been removed because of
CIED infection. In Japan, because most patients with CIED infec-
tion are not discharged until a new CIED is implanted and are
monitored by a telemetry device, the rate of sudden death during
the waiting period is low. However, WCD seems to be safer than
only monitoring, even when the patients are hospitalized.
Fig. 5. Totally subcutaneous implantable cardioverter deﬁbrillator.
Fig. 6. Before removal of the CIED. The old pacemaker leads were implanted from left side, and a new CRT-D was implanted from the right.
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(Fig. 5) are reportedly as safe and effective as transvenous ICD systems
[10]. S-ICDs are beneﬁcial because they carry no risk of vascular
injury, have a low risk of systemic infection, and have no need for
ﬂuoroscopy. Although S-ICDs are not a temporary system, they may
be suitable for early reimplantation in patients at a high risk of
tachyarrhythmia.We encountered one case of successful ablation before rem-
oval of an infected CRT-D. The patient was a 72-year-old woman
with complete AV block, sustained VT, and cardiac sarcoidosis.
The VT was controlled using amiodarone and pilsicainide, but a
VT storm occurred after pilsicainide was withdrawn. Because the
LV ejection fraction was less than 30%, ablation was attempted
before pilsicainide was restarted. The VT was ﬁnally eliminated
N. Nishii / Journal of Arrhythmia 32 (2016) 287–292 291by catheter ablation, and it did not recur after implantation of a
new CIED. Thus, catheter ablation may be another useful method
for managing tachyarrhythmia during the waiting period.Fig. 7. Temporary DDD pacing. Temporary atrial and ventricular leads were
implanted from the right jugular vein.
Fig. 8. Before removal of the CIED. Atrial and ICD leads were implanted transvenou5. Patients dependent on CRT
In patients dependent on CRT, it is very difﬁcult to maintain
hemodynamics by using temporary VVI pacing after CIED removal.
To our knowledge, no study has reported temporary CRT pacing
until new CIED implantation.
We encountered two cases in which temporary sequential pacing
was used during the waiting period. The ﬁrst was that of a 77-year-
old man who suffered from a complete AV block, sustained VT, and
cardiac sarcoidosis. His pacemaker was upgraded to CRT-D (Fig. 6),
and pocket infection occurred 3 years later. However, the patient was
pacing dependent and responded to CRT. Before lead extraction, a
hemodynamic test was performed. VVI pacing instead of CRT aggra-
vated the hemodynamic state (cardiac index [CI]¼2.27 L min1 m2
in DDD with BiV pacing; 1.76 L min1 m2 in VVI with RV pacing).
After lead extraction, temporary DDD pacing was used (Fig. 7) with
intravenous catecholamine infusion. The hemodynamic state was
maintained for 2 weeks, and a new CRT-D was successfully implanted
after the infection disappeared. The other case was that of a 72-year-
old woman with complete AV block, sustained VT, and cardiac sar-
coidosis. Her pacemaker was upgraded to CRT-D at the time of mitral
valve replacement, and the LV lead was an epicardial lead (Fig. 8). The
patient contracted a pocket infection 4 years after CRT-D implanta-
tion. A hemodynamic test was performed before lead removal.
VVI pacing instead of CRT aggravated the hemodynamic state
(CI¼1.95 L min1 m2 in DDD with BiV pacing; 1.74 L min1 m2 in
DDD with only RV pacing; 1.45 L min1 m2 in VVI with RV pacing).
The lateral chest wall was opened to remove the LV epicardial lead,
but because of adhesion of the left lung, the LV lead was only partially
removed. Temporary epicardial atrial and LV leads were implanted. A
temporary RV lead (with a permanent active ﬁxation lead) was also
implanted from the right jugular vein. DDD with Biventricular pacing
could be delivered from the three leads (Fig. 9). The hemodynamic
state was maintained for 2 weeks, and a new CRT-D was successfullysly. A left ventricular epicardial lead was implanted during open heart surgery.
Fig. 9. Temporary DDD with biventricular pacing. Temporary epicardial atrial and
left ventricular leads were implanted, while a temporary right ventricular lead was
implanted transvenously.
N. Nishii / Journal of Arrhythmia 32 (2016) 287–292292implanted after infection disappeared. We have never used a tem-
porary transvenous LV lead, which may be required in some cases.6. Summary
Various methods can be used for arrhythmic management
during the waiting period before new CIED implantation. The aim
should be to use an appropriate method to prevent the occurrence
of arrhythmic events.Conﬂict of interest
The author declares no conﬂict of interest related to this study.References
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